The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases and reviews issues related to the preparation, dispensing, and administration of cancer chemotherapy.
BodrogiI., BakiM., HortiJ.Vinblastine, cisplatin, and bleomycin treatment of advanced nonseminomatous testicular tumors.Neoplasma.1990; 37: 445–50.
3.
EinhornL.H., DonohueJ.Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.Ann Int Med.1977; 87: 293–8.
4.
StoterG., SleyferD.T., HuininkW.W.High dose versus low-dose vinblastine incisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group.J Clin Oncol.1986; 4: 1199–206.
5.
EinhornL.H.Testicular cancer: An oncological success story.Clin Can Res.1997; 3: 2630–2.
6.
WilliamsS.D., BirchR., EinhornL.H.Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide.N Engl J Med.1987; 316: 1435–40.
7.
WeissR.B., StableinD.M., MuggiaF.M.Toxicity comparisons between two chemotherapy regimens as adjuvant or salvage treatment in nonseminomatous testicular cancer.Cancer.1988; 62: 18–23.
8.
BergerA.M., Clark-SnowR.A.Nausea and vomiting. In: DeVitaV.T., HellmanS., RosenbergS.A., eds. Cancer: Principles and Practice of Oncology.5th ed.Philadelphia, PA: Lippincott-Raven Publishers; 1997, 2705–14.
9.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy.J Clin Oncol.1997; 15(1): 103–9.
10.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery.Am J Health Syst Pharm.1999; 56: 729–64.
11.
NCCN antiemesis practice guidelines v.1. 2003. The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM]. Version 2003.Rockledge, PA: National Comprehensive Cancer Network; 2003.
12.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines.J Clin Oncol.1999; 17(9): 2971–94.
13.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.Gynecol Oncol.1993; 50: 147–58.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines.J Clin Oncol.2000; 18(20): 3558–85.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: Implications for the use of colony-stimulating factors.Eur J Cancer.1998; 34(12): 1857–64.
19.
LymanG.H., BalducciL.Update of the economic analyses of the use of colony stimulating factors.Curr Opin Hematol.1999; 6(3): 145–51.
20.
LarsonD.L.Treatment of tissue extravasation by antitumor agents.Cancer.1982; 49(9): 1796–9.
21.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surgery.1985; 75(3): 397–402.
22.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury.Hosp Pharm.2000; 35: 57–74.
23.
HansenS.W.Late effects after treatment for germ-cell cancer with cisplatin, vinblastine, and bleomycin.Danish Medical Bull.1992; 39: 391–9.
24.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function.Cancer Treat Rev.1995; 21: 33–64.
25.
PattersonW.P., ReamsG.P.Renal and electrolyte abnormalities due to chemotherapy. In: The Chemotherapy Sourcebook.3rd ed.PerryM.C., ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2001, 494–504.
26.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents.Gastroenterol Clin North Am.1995; 24(4): 969–89.
27.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic agents. In: The Chemotherapy Sourcebook.3rd ed.PerryM.C., ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001, 483–93.
